Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
ipo
4
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
cancer
cancer drugs
clinical trials
amgen
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
fda
glaxosmithkline
indiana blog main
indiana top stories
loxo oncology
medicare
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
revolution medicines
san diego blog main
san diego top stories
san francisco
sanofi
scott gottlieb
seattle blog main
seattle top stories
texas blog main
texas top stories
the column group
What
cancer
4
×
ipo
bio
medicines
pharmaceutical
proteins
research
revolution
roundup
allogene
appetite
black
bread
butter
buyout
cancer’s
cash
crispr
despite
diabetes
diamond’s
disease
diversity
drug
drugs
eli
family
frontiers
giant
grabbed
hardest
hasn’t
hit
hold
hot
hottest
hunters
immunotherapy
investors
juno
Language
unset
Current search:
ipo
×
cancer
×
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
